---
layout: default
title: Copper Sulfate
parent: 僅模型預測 (L5)
nav_order: 148
evidence_level: L5
indication_count: 0
---

# Copper Sulfate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Copper Sulfate: Drug Repurposing Evaluation — Insufficient Data for Prediction

## One-Sentence Summary

Copper Sulfate is an inorganic copper salt with historical medical applications; however, no original approved indications are recorded in this dataset and no DrugBank identifier has been assigned.
The TxGNN model was unable to generate any repurposing predictions for this compound, most likely because the missing DrugBank ID prevents knowledge graph mapping.
As a result, **no predicted new indication, supporting clinical trials, or linked publications** are available for evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## South Africa Market Information

Copper Sulfate holds **no current SAHPRA registrations** and is not marketed in South Africa. No product name, dosage form, or approved indication data is available from the regulatory record.

> If the compound is intended to reach South African patients, a full SAHPRA registration dossier would need to be submitted. Check whether any Section 21 (unregistered medicine) authorisations exist for specific clinical settings.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

> Note: Two blocking data gaps were identified in the evidence review. Warnings and contraindications from the SAHPRA or TFDA PI could not be retrieved (DG001 — Severity: Blocking), and mechanism of action data is absent (DG002 — Severity: High). Neither safety nor efficacy assessment can proceed until these gaps are resolved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction pipeline could not process Copper Sulfate because no DrugBank ID has been assigned and no original indications are recorded, making knowledge graph mapping impossible. Without a prediction, no repurposing direction, clinical trial evidence, or mechanistic rationale can be evaluated.

**To proceed, the following is needed:**

- **Resolve DG001 (Blocking):** Download and parse the SAHPRA or TFDA Professional Information (PI) PDF to extract approved warnings and contraindications — this is required before any safety screening can begin
- **Resolve DG002 (High):** Query the DrugBank API to retrieve a valid DrugBank ID and mechanism of action for Copper Sulfate
- **Confirm original indication(s):** Identify at least one approved therapeutic use from a recognised regulatory authority (e.g., WHO Essential Medicines, EMA, FDA, SAHPRA) and record it in the drug profile
- **Re-run the TxGNN pipeline:** Once a DrugBank ID and original indication are in place, re-run the knowledge graph and deep learning prediction steps to generate repurposing candidates
- **Assess antineoplastic status:** After MOA data is retrieved, determine whether Copper Sulfate qualifies for cytotoxicity screening under South African cytotoxic handling regulations
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

